GlassScriptPhysician profile
Zafar Hossain
NPI 1316997257
$2,598.83
in general payments reported to CMS, 2019-2025
26 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $95.23 · 2022: $118 · 2023: $444 · 2024: $783 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $530.21 | 2019-2025 | |
| Novo Nordisk INC | $351.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $277.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $182.97 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $172.18 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $140.26 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $101.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $91.91 | 2023-2025 | |
| Amgen INC. | $83.26 | 2019-2025 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $82.94 | 2024-2025 | |
| Exact Sciences Corporation | $76.06 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.62 | 2019 | |
| Lilly USA, LLC | $48.60 | 2019-2023 | Mounjaro, Trulicity |
| Abiomed | $44.64 | 2024-2025 | Impella |
| Astellas Pharma US INC | $43.96 | 2023-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.54 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $42.81 | 2019-2025 | Eliquis, Camzyos |
| Arbor Pharmaceuticals, INC. | $31.38 | 2019 | |
| Philips North America LLC | $29.22 | 2019 | |
| Phathom Pharmaceuticals, INC. | $27.93 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $26.50 | 2019-2020 | |
| Daiichi Sankyo INC. | $24.45 | 2022 | |
| Boston Scientific Corporation | $20.56 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $19.70 | 2025 | Inspire |
| Medtronic, INC. | $18.40 | 2025 | Intellis Adaptivestim |
| Melinta Therapeutics, LLC | $17.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zafar Hossain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.